RT Journal Article
SR Electronic
T1 Correlation of Phosphorylated HER2 with Clinicopathological Characteristics and Efficacy of Trastuzumab Treatment for Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2509
OP 2515
VO 33
IS 6
A1 SNJEŽANA RAMIĆ
A1 KSENIJA ASIĆ
A1 MELITA PERIĆ BALJA
A1 FRANE PAIĆ
A1 VESNA BENKOVIĆ
A1 FABIJAN KNEŽEVIĆ
YR 2013
UL http://ar.iiarjournals.org/content/33/6/2509.abstract
AB Aim: To determine the correlation of phosphorylated human epidermal growth factor receptor-2 (pHER2) with clinicopathological characteristics of breast cancer (BC) and patients' response to trastuzumab-based therapy. Patients and Methods: pHER2 was determinated immuno-histochemically in 88 cases of HER2-positive and 50 cases of HER2-negative BC. All patients with HER2-positive BC received trastuzumab-based therapy and 16 of them (18.2%) had disease progression during therapy treatment (i.e. trastuzumab-resistant). Results: pHER2 was predominantly expressed in HER2-positive BC, with 55 cases (62.5%) of tumours expressing pHER2. Six cases of HER2-negative cancer (12.5%) displayed positive expression of pHER2. Expression of pHER2 correlated with younger age of patients and negative oestrogen receptor status. Acquisition of resistance to trastuzumab correlated with negativity for pHER2 (p=0.028). Conclusion: Positive expression of pHER2 may yield additional information regarding the poor prognosis of BC and could be used for pre-selection of patients with HER2-overexpressing BC displaying resistance to trastuzumab treatment.